Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.51 USD

73.51
8,119,563

+0.21 (0.29%)

Updated Jul 18, 2024 04:00 PM ET

After-Market: $73.37 -0.14 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New Strong Sell Stocks for February 10th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

The Zacks Analyst Blog Highlights: Exxon Mobil, Chevron, IBM, Gilead and Edwards Lifesciences

Neena Mishra headshot

Can Biotech ETFs Continue to Soar in 2020?

We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.

Company News for Feb 6, 2020

Companies In The News Are: COTY, CPRI, HUM, GILD.

Sheraz Mian headshot

Coronavirus Starting to Weigh on 2020 Q1 Earnings Estimates

In addition to featuring fresh research reports on Exxon (XOM), Chevron (CVX), IBM (IBM) and others, today's Research Daily provides the Q4 earnings season update.

Regeneron Expands Agreement to Develop Coronavirus Therapy

Regeneron (REGN) expands its agreement with U.S. Department of Health and Human Services for development of a therapy for newly found coronavirus.

Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod

Many biotech bigwigs came out with their fourth-quarter numbers in the past week.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.

The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap

The Zacks Analyst Blog Highlights: Disney, Chipotle, Ford, Gilead and Snap

Mark Vickery headshot

Disney, Gilead & Snap Post Mixed Quarters, Chipotle Beats

Lots of fresh Q4 earnings results to sift through after Tuesday's closing bell, so we will dive right in.

Gilead Sciences (GILD) Misses Q4 Earnings Estimates

Gilead (GILD) delivered earnings and revenue surprises of -22.62% and 2.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Company News for Feb 4, 2020

Companies in the news are: GILD, MAXR, INSM, ABG

Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Should You Buy Gilead (GILD) Ahead of Earnings?

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.

Will Strong HIV Sales Drive Gilead's (GILD) Q4 Earnings?

Investors will focus on the performance of the HIV franchise and the uptake of Yescarta along with pipeline updates, when Gilead (GILD) reports fourth-quarter 2019 results.

J&J (JNJ) Plans to Develop Vaccine for New Coronavirus

J&J (JNJ) is looking to develop a vaccine for the new coronavirus infection. Its drug Erleada's label is expanded to include new prostate cancer patient population in Europe.

Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation

Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $64.36 in the latest trading session, marking a +0.83% move from the prior day.

Sanghamitra Saha headshot

Wining & Losing ETF Areas on Coronavirus Outbreak

Coronavirus outbreak puts these ETF areas in winning and losing positions.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.